138 filings
8-K
SYRE
Spyre Therapeutics Inc.
25 Apr 24
Unregistered Sales of Equity Securities
4:21pm
8-K
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
SYRE
Spyre Therapeutics Inc.
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
SYRE
Spyre Therapeutics Inc.
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
SYRE
Spyre Therapeutics Inc.
18 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:26pm
8-K
9w14ngsk
8 Dec 23
Spyre Therapeutics Announces $180 Million Private Placement
8:45am
8-K
6tyiv9y7 vw
28 Nov 23
Appoints CEO and Additional Directors, and Expands Leadership Team to
7:33am
8-K
unfjfrujpk1lw
22 Nov 23
Amendments to Articles of Incorporation or Bylaws
8:45pm
8-K
5a3zs2hw5hr
15 Nov 23
Other Events
5:14pm
8-K
xfx37fyf
9 Nov 23
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
evd4g6 kvnjrr60
24 Oct 23
Regulation FD Disclosure
9:00am
8-K
b1qtwbc8koe gvibc4
10 Oct 23
Report of Independent Registered Public Accounting Firm
12:00am
8-K
bfq0luf
5 Oct 23
Entry into a Material Definitive Agreement
5:13pm
8-K
4otih16pj37h8aofrxp
25 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
m6j6 k3z0hwi
8 Sep 23
Material Modifications to Rights of Security Holders
5:05pm
8-K
p2l6y
5 Sep 23
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
7:06am
8-K
g1mm3
11 Aug 23
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
7:02am
8-K
50bws 61vunm0iwn1t9o
11 Aug 23
Termination of a Material Definitive Agreement
7:01am
8-K
r54cdpq1odqkn8xlvl7k
27 Jul 23
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
7:01am
8-K
1573g wxlbrdf
14 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm